Aldeyra Therapeutics (ALDX) Retained Earnings (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Retained Earnings of -$487.4 million for Q1 2026, down 0.71% on a QoQ basis from -$484.0 million in Q4 2025, and down 5.95% year-over-year from -$518.2 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Retained Earnings (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Retained Earnings history runs 14 years deep, the most recent figure standing at -$487.4 million for Q1 2026.
- Quarterly Retained Earnings fell 5.95% year-over-year to -$487.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$487.4 million (down 5.95% YoY) and the FY2025 annual result came in at -$484.0 million, down 7.52% from the prior year.
- Retained Earnings was -$487.4 million for Q1 2026 at Aldeyra Therapeutics, down from -$484.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $66540.0 in Q3 2024 and bottomed at -$487.4 million in Q1 2026.
- A 5-year average of -$284.1 million and a median of -$395.8 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 100.0% — and 2025, when it slumped 15187753.85%.
- Aldeyra Therapeutics' Retained Earnings stood at -$356.7 million in 2022, then slipped by 4.38% to -$372.3 million in 2023, then retreated by 20.89% to -$450.1 million in 2024, then dropped by 7.52% to -$484.0 million in 2025, then decreased by 0.71% to -$487.4 million in 2026.
- Business Quant data shows ALDX's Retained Earnings at -$487.4 million in Q1 2026, -$484.0 million in Q4 2025, and -$477.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Aldeyra Therapeutics | 93.49 Mn | 93.49 Mn | - | -487.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -487.41 Mn |
| Dec 31, 2025 | -483.96 Mn |
| Sep 30, 2025 | -477.50 Mn |
| Jun 30, 2025 | -469.81 Mn |
| Mar 31, 2025 | -460.04 Mn |
| Dec 31, 2024 | -450.11 Mn |
| Sep 30, 2024 | 66,540.00 |
| Jun 30, 2024 | -419.19 Mn |
| Mar 31, 2024 | -3,029.00 |
| Mar 31, 2023 | -372.33 Mn |
| Dec 31, 2022 | -356.72 Mn |
| Sep 30, 2022 | -285,733.00 |
| Jun 30, 2022 | -285,763.00 |
| Mar 31, 2022 | -61,677.00 |
| Dec 31, 2021 | -294.69 Mn |
| Sep 30, 2021 | -278.94 Mn |
| Jun 30, 2021 | -263.14 Mn |
| Mar 31, 2021 | -248.21 Mn |
| Dec 31, 2020 | -236.92 Mn |
| Sep 30, 2020 | -225.62 Mn |